Literature DB >> 22331282

Heparanase enzyme in chronic inflammatory bowel disease and colon cancer.

Esther Hermano1, Immanuel Lerner, Michael Elkin.   

Abstract

Heparanase is the sole mammalian endoglycosidase that cleaves heparan sulfate, the key polysaccharide of the extracellular matrix and basement membranes. Enzymatic cleavage of heparan sulfate profoundly affects a variety of physiological and pathological processes, including morphogenesis, neovascularization, inflammation, and tumorigenesis. Critical involvement of heparanase in colorectal tumor progression and metastatic spread is widely documented; however, until recently a role for heparanase in the initiation of colon carcinoma remained underappreciated. Interestingly, the emerging data that link heparanase to chronic inflammatory bowel conditions, also suggest contribution of the enzyme to colonic tumor initiation, at least in the setting of colitis-associated cancer. Highly coordinated interplay between intestinal heparanase and immune cells (i.e., macrophages) preserves chronic inflammatory conditions and creates a tumor-promoting microenvironment. Here we review the action of heparanase in colon tumorigenesis and discuss recent findings, pointing to a role for heparanase in sustaining immune cell-epithelial crosstalk that underlies intestinal inflammation and the associated cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22331282     DOI: 10.1007/s00018-012-0930-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  174 in total

Review 1.  Heparan sulfate proteoglycans: intricate molecules with intriguing functions.

Authors:  R V Iozzo
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member.

Authors:  E McKenzie; K Tyson; A Stamps; P Smith; P Turner; R Barry; M Hircock; S Patel; E Barry; C Stubberfield; J Terrett; M Page
Journal:  Biochem Biophys Res Commun       Date:  2000-10-05       Impact factor: 3.575

3.  Heparanase mediates cell adhesion independent of its enzymatic activity.

Authors:  Orit Goldshmidt; Eyal Zcharia; Miriam Cohen; Helena Aingorn; Irit Cohen; Liat Nadav; Ben-Zion Katz; Benjamin Geiger; Israel Vlodavsky
Journal:  FASEB J       Date:  2003-06       Impact factor: 5.191

Review 4.  Heparin, heparan sulfate and heparanase in inflammatory reactions.

Authors:  Jin-Ping Li; Israel Vlodavsky
Journal:  Thromb Haemost       Date:  2009-11       Impact factor: 5.249

Review 5.  Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance.

Authors:  L Caradonna; L Amati; T Magrone; N M Pellegrino; E Jirillo; D Caccavo
Journal:  J Endotoxin Res       Date:  2000

6.  Role of endothelial heparanase in delayed-type hypersensitivity.

Authors:  Evgeny Edovitsky; Immanuel Lerner; Eyal Zcharia; Tamar Peretz; Israel Vlodavsky; Michael Elkin
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

7.  Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.

Authors:  Agnes Y Y Lee; Frederick R Rickles; Jim A Julian; Michael Gent; Ross I Baker; Chris Bowden; Ajay K Kakkar; Martin Prins; Mark N Levine
Journal:  J Clin Oncol       Date:  2005-02-07       Impact factor: 44.544

8.  Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice.

Authors:  Martin Floer; Martin Götte; Martin K Wild; Jan Heidemann; Ezeddin Salem Gassar; Wolfram Domschke; Ludwig Kiesel; Andreas Luegering; Torsten Kucharzik
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

9.  Carcinogenesis in inflammatory bowel disease.

Authors:  Laszlo Herszenyi; Pal Miheller; Zsolt Tulassay
Journal:  Dig Dis       Date:  2007       Impact factor: 2.404

10.  Treatment of corticosteroid-resistant ulcerative colitis with heparin--a report of 16 cases.

Authors:  R C Evans; V S Wong; A I Morris; J M Rhodes
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171

View more
  18 in total

1.  The potential of heparanase as a therapeutic target in cancer.

Authors:  Claudio Pisano; Israel Vlodavsky; Neta Ilan; Franco Zunino
Journal:  Biochem Pharmacol       Date:  2014-02-22       Impact factor: 5.858

2.  Modification of heparanase gene expression in response to conditioning and LPS treatment: strong correlation to rs4693608 SNP.

Authors:  Olga Ostrovsky; Avichai Shimoni; Polina Baryakh; Yan Morgulis; Margarita Mayorov; Katia Beider; Anna Shteingauz; Neta Ilan; Israel Vlodavsky; Arnon Nagler
Journal:  J Leukoc Biol       Date:  2013-12-06       Impact factor: 4.962

3.  Unfractionated heparin attenuates intestinal injury in mouse model of sepsis by inhibiting heparanase.

Authors:  Song Chen; Xiaojuan Zhang; Yini Sun; Ziwei Hu; Siyu Lu; Xiaochun Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 4.  Heparanase: From basic research to therapeutic applications in cancer and inflammation.

Authors:  Israel Vlodavsky; Preeti Singh; Ilanit Boyango; Lilach Gutter-Kapon; Michael Elkin; Ralph D Sanderson; Neta Ilan
Journal:  Drug Resist Updat       Date:  2016-10-06       Impact factor: 18.500

Review 5.  Involvement of heparanase in atherosclerosis and other vessel wall pathologies.

Authors:  Israel Vlodavsky; Miry Blich; Jin-Ping Li; Ralph D Sanderson; Neta Ilan
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

Review 6.  Opposing Functions of Heparanase-1 and Heparanase-2 in Cancer Progression.

Authors:  Israel Vlodavsky; Miriam Gross-Cohen; Marina Weissmann; Neta Ilan; Ralph D Sanderson
Journal:  Trends Biochem Sci       Date:  2017-11-20       Impact factor: 13.807

Review 7.  Heparanase in inflammation and inflammation-associated cancer.

Authors:  Amichay Meirovitz; Rachel Goldberg; Adi Binder; Ariel M Rubinstein; Esther Hermano; Michael Elkin
Journal:  FEBS J       Date:  2013-03-04       Impact factor: 5.542

8.  Heparanase is preferentially expressed in human psoriatic lesions and induces development of psoriasiform skin inflammation in mice.

Authors:  Immanuel Lerner; Eyal Zcharia; Tzahi Neuman; Esther Hermano; Ariel M Rubinstein; Israel Vlodavsky; Michael Elkin
Journal:  Cell Mol Life Sci       Date:  2013-10-30       Impact factor: 9.261

9.  Helicobacter pylori-Induced Heparanase Promotes H. pylori Colonization and Gastritis.

Authors:  Li Tang; Bo Tang; Yuanyuan Lei; Min Yang; Sumin Wang; Shiping Hu; Zhuo Xie; Yaojiang Liu; Israel Vlodavsky; Shiming Yang
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

10.  Heparanase interacts with resistin and augments its activity.

Authors:  Daniela Novick; Sara Barak; Neta Ilan; Israel Vlodavsky
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.